Bayer Connects With Genaissance and Uses SNP-Dx to Re-enter Statin Space | GenomeWeb

Hoping to cash in on a market that appears to favor diagnostics over therapeutics, Bayer Diagnostics and Genaissance Pharmaceuticals intend to co-develop SNP-based diagnostic assays for a trio of common and potentially lucrative disease areas.

One of these areas, antihypercholesterolemia, will reacquaint Bayer with statins, a drug category the company chose to abandon two years ago after its entrant Baycol became linked to patient deaths.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.